Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-DF vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4; first-pass metabolism; ~90% metabolized, <10% excreted unchanged.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to plasma proteins, primarily albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
Apparent volume of distribution: 0.45 L/kg; distributes freely into body water, with higher distribution in neonates and patients with liver disease.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral immediate-release: 96–100%; oral extended-release (Somophyllin-DF): 80–100% relative to intravenous, with reduced absorption due to slower release.
Oral: 40-50%; Inhalation: 20-30%
No dose adjustment required for renal impairment. However, monitor serum levels in patients with renal failure receiving theophylline as metabolites may accumulate.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 60-75%. Child-Pugh Class C: Reduce dose by 80-90%. Monitor serum levels closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Oral: Initial 16 mg/kg/day or 400 mg/day (whichever is less) in divided doses every 12 hours; extended-release. Adjust based on serum levels. Maximum 20 mg/kg/day or 800 mg/day.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Elderly patients: Start at lower end of dosing range, 300-400 mg/day in divided doses. Monitor serum levels frequently due to decreased clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Cardiovascular toxicity (arrhythmias), seizure risk, hypersensitivity reactions, interactions with fluoroquinolones and macrolides, smoking cessation reduces clearance, monitor serum theophylline levels.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or xanthines, active peptic ulcer disease, uncontrolled seizure disorders.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate, energy drinks) as it can increase stimulant effects and risk of toxicity. Charcoal-broiled foods may increase metabolism of theophylline, potentially reducing effectiveness. High-protein/low-carbohydrate diets may reduce clearance; high-carbohydrate/low-protein diets may increase clearance. Grapefruit juice does not significantly interact, but consistent intake pattern is advised.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Second/third trimester: Fetal tachycardia, irritability, and jitteriness can occur due to transplacental passage; risk of neonatal withdrawal if used near term. Avoid high doses near delivery.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with a milk-to-plasma ratio approximately 0.67. Infant serum levels can reach therapeutic or toxic concentrations, especially in preterm or neonatal infants. Caution advised; monitor infant for irritability or poor feeding. Use only if clearly needed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Clearance of theophylline decreases in the third trimester due to reduced hepatic metabolism. Doses may need reduction by 20-30% compared to non-pregnant state, guided by trough serum concentrations. Increase monitoring frequency (every 1-2 weeks) during dose adjustments.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Verify controlled-release properties: do not crush or chew tablets. Monitor theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Use with caution in patients with CHF, hepatic impairment, or febrile illness as clearance may decrease. Cigarette smoking increases clearance; adjust dose accordingly. Concurrent use with cimetidine, fluoroquinolones, or macrolides can significantly increase levels.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not skip doses or double up. Swallow tablets whole—do not crush or chew. Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects. Report symptoms of toxicity: persistent nausea, vomiting, insomnia, jitteriness, or rapid heart rate. Do not smoke or stop smoking without telling your doctor; smoking changes how this medicine works. Keep all appointments for blood tests to check drug levels. Store at room temperature, away from moisture and heat.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-DF vs AEROLATE III, answered by our medical review team.
SOMOPHYLLIN-DF is a Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-DF and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-DF is: Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-DF and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-DF is classified as Category C. Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Sec. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.